0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > OSMR

OSMR

Brief Information

Name:Oncostatin-M-specific receptor subunit beta
Target Synonym:IL-31R-beta,IL-31RB,Interleukin-31 receptor subunit beta,IL-31 receptor subunit beta,IL-31R subunit beta
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
OSR-C52H8 Canine Canis lupus OSMR beta Protein, His Tag (MALS verified)
OSR-C52H8-structure
OSR-C52H8-sds
OSR-H52H9 Human Human OSMR beta Protein, His Tag (MALS verified)
OSR-H52H9-structure
OSR-H52H9-sds
OSR-C52H9 Cynomolgus Cynomolgus OSMR beta Protein, His Tag (MALS verified)
OSR-C52H9-structure
OSR-C52H9-sds
ACRO Quality

Part of Bioactivity data

OSR-C52H8-MALS-HPLC
OSMR MALS images

The purity of Canis lupus OSMR beta Protein, His Tag (Cat. No. OSR-C52H8) is more than 90% and the molecular weight of this protein is around 105-125 kDa verified by SEC-MALS.

OSR-H52H9-MALS-HPLC
OSMR MALS images

The purity of Human OSMR, His Tag (Cat. No. OSR-H52H9) is more than 85% and the molecular weight of this protein is around 105-125 kDa verified by SEC-MALS.

Synonym Name

Oncostatin-M-specific receptor subunit beta,Interleukin-31 receptor subunit beta,IL-31 receptor subunit beta,IL-31R subunit beta,IL-31R-beta,IL-31RB,OSMR,OSMRB

Background

Oncostatin-M-specific receptor subunit beta(OSMRB) alos know as Interleukin-31 receptor subunit beta (IL-31RB), is an alternative subunit (OSMRβ) for an OSM receptor complex (a heterodimer of gp130 and OSMRβ), that is activated by OSM but not by LIF. OSMR beta associates with the low affinity OSM·gp130 complex to form a high affinity heterodimeric receptor that is capable of transducing OSM-specific signaling events.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vixarelimab RO-7622888; RG-6536; KPL-716; BIIB-069 Phase 2 Clinical Biogen Inc Pruritus; Chronic Urticaria; Psoriasis; Prurigo; Lichen Planus; Neurodermatitis; Colitis, Ulcerative Details
Vixarelimab RO-7622888; RG-6536; KPL-716; BIIB-069 Phase 2 Clinical Biogen Inc Pruritus; Chronic Urticaria; Psoriasis; Prurigo; Lichen Planus; Neurodermatitis; Colitis, Ulcerative Details

This web search service is supported by Google Inc.

totop

Nachricht schicken